Form 4: Humacyte Director Michael T. Constantino Increases Stake with $1.26 Share Purchase

Director Michael T. Constantino increased his holdings in Humacyte, Inc. by purchasing 16,000 shares of common stock at an average price of $1.26 on April 7, 2025.

Summary

• On April 7, 2025, Michael T. Constantino, a director of Humacyte, Inc., purchased 16,000 shares of the company's common stock.
• The shares were bought at a weighted average price of $1.26, with individual prices ranging from $1.255 to $1.26 per share.
• Following the transaction, Constantino directly owns 32,950 shares of Humacyte common stock.

Sentiment

Score: 6

Explanation: A director purchasing shares is generally a positive sign, but the transaction is relatively small and doesn't drastically alter the overall outlook.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, allowing investors to track confidence levels and potential alignment of interests.

Stakeholder Impact

• The stock purchase by a director could positively influence shareholder sentiment.

Key Dates

Keywords

Humacyte, Director, Stock Purchase, Michael T. Constantino, Form 4, Beneficial Ownership, HUMA